Scientist doing research

The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), led by Murdoch Children’s Research Institute Chief Scientist Professor Melissa Little AC, has released its 2023 annual report.

reNEW is a global consortium that focuses on translating stem cell science into therapies at its three research nodes, the University of Copenhagen, Leiden University Medical Center, and Murdoch Children's Research Institute in Melbourne.

20221209 Little Melissa WEB 01

Image: reNEW CEO and MCRI Chief Scientist Professor Melissa Little

“After an incredible launch in 2022, we are reaching flight altitude, and 2023 was another great year of stem cell science and translation,” reNEW CEO Professor Little said.

The 2023 Annual Report highlights progress made on excellent stem cell research towards the understanding of human development and disease, and potential therapies for these diseases.

reNEW researchers are working on developing cell and gene-modified cell-based advanced therapeutic medicinal products (ATMPs), as well as identifying new therapies screened on stem cell models of human tissues.

Excitingly, reNEW researchers are currently involved in two clinical trials.

“We have seen Associate Professor Agnete Kirkeby and her Lund team reach phase 1/2a clinical trial for the treatment of Parkinson’s disease via the injection of human embryonic stem cell-derived dopaminergic neurons,” Professor Little said.

“reNEW is supporting the team to develop additional neural cell types.”

“The RAG-1 SCID clinical trial started by Professor Frank Staal in Leiden in 2021 has, thanks to the support of reNEW, opened a clinical trial site in Melbourne,” Professor Little added.

Learn more about the work MCRI researchers in the reNEW Melbourne node are undertaking.

child in hospital

Tomorrow's cures need your donations today

Donate now